Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 75.28 percent increase over losses of $(0.89) per share from the same period last year. The company reported quarterly sales of $(1.208 million) which missed the analyst consensus estimate of $5.025 million by 124.04 percent.